Literature DB >> 7824046

The effect of cyclopyrrolones on GABAA receptor function is different from that of benzodiazepines.

A Concas1, M Serra, G Santoro, E Maciocco, T Cuccheddu, G Biggio.   

Abstract

The effects of the cyclopyrrolones zopiclone and suriclone on the function of the central gamma-amino-butyric acid type A (GABAA) receptor complex in mouse brain were evaluated both in vitro and in vivo. Added in vitro to mouse cerebral cortical membranes, these compounds potently inhibited [3H]flumazenil binding with IC50 (50% inhibitory concentration) values of 35.8 nM (zopiclone) and 1.1 nM (suriclone). Similar results were obtained with cerebellar membranes, indicating that these drugs do not discriminate between putative type I and type II benzodiazepine receptors. The interaction of cyclopyrrolones with recognition sites present at the level of the GABA receptor complex appears to be competitive, because zopiclone decreased the affinity of the receptors for [3H]flumazenil without affecting the maximal number of binding sites. Moreover, zopiclone and suriclone did not affect the rate of dissociation of [3H]flumazenil from benzodiazepine receptors. The in vitro efficacy of zopiclone appeared different from that of suriclone and the benzodiazepines diazepam and flunitrazepam. Thus, zopiclone failed to affect muscimol-stimulated 36Cl- uptake and only slightly inhibited t-[35S]butylbicyclophosphorothionate ([35S]TBPS) binding. In contrast, like diazepam and flunitrazepam, suriclone increased muscimol-stimulated 36Cl- uptake and markedly inhibited [35S]TBPS binding. In contrast, like diazepam and flunitrazepam, suriclone increased muscimol-stimulated 36Cl- uptake and markedly inhibited [35S]TBPS binding. On the other hand, suriclone, like zopiclone, did not modify [3H]muscimol binding to mouse cerebral cortical membranes. Moreover, zopiclone antagonized the reduction in [35S]TBPS binding elicited by the benzodiazepine receptor full of agonist diazepam. Consistent with its low efficacy in vitro, oral administration of zopiclone (2.5 to 100 mg/kg, p.o.) in mice failed to modify [35S]TBPS binding subsequently measured in cerebral cortical membranes "ex vitro".(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7824046     DOI: 10.1007/bf00175035

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  21 in total

1.  Studies on the dependence-inducing potential of zopiclone and triazolam.

Authors:  K Boissl; J F Dreyfus; M Delmotte
Journal:  Pharmacology       Date:  1983       Impact factor: 2.547

2.  Evaluation of zopiclone physical dependence liability in normal volunteers.

Authors:  P Dorian; E M Sellers; H Kaplan; C Hamilton
Journal:  Pharmacology       Date:  1983       Impact factor: 2.547

3.  The convulsant action of hydrazides and regional changes in cerebral gamma-aminobutyric acid and pyridoxal phosphate concentrations.

Authors:  R W Horton; A G Chapman; B S Meldrum
Journal:  J Neurochem       Date:  1979-09       Impact factor: 5.372

4.  Isoniazid, an inhibitor of GABAergic transmission, enhances [35S]TBPS binding in rat cerebral cortex.

Authors:  M Serra; E Sanna; G Biggio
Journal:  Eur J Pharmacol       Date:  1989-05-19       Impact factor: 4.432

5.  Effect of the cyclopyrrolones suriclone and RP 59037 on body temperature in mice.

Authors:  H C Jackson; E Ramsay; D J Nutt
Journal:  Eur J Pharmacol       Date:  1992-05-27       Impact factor: 4.432

6.  Suriclone: a new cyclopyrrolone derivative recognizing receptors labeled by benzodiazepines in rat hippocampus and cerebellum.

Authors:  J C Blanchard; L Julou
Journal:  J Neurochem       Date:  1983-03       Impact factor: 5.372

7.  Full and partial agonism displayed by benzodiazepine receptor ligands at recombinant gamma-aminobutyric acidA receptor subtypes.

Authors:  F Knoflach; U Drescher; L Scheurer; P Malherbe; H Mohler
Journal:  J Pharmacol Exp Ther       Date:  1993-07       Impact factor: 4.030

8.  Anxiolytic cyclopyrrolones zopiclone and suriclone bind to a novel site linked allosterically to benzodiazepine receptors.

Authors:  R R Trifiletti; S H Snyder
Journal:  Mol Pharmacol       Date:  1984-11       Impact factor: 4.436

Review 9.  Novel anxiolytics that act as partial agonists at benzodiazepine receptors.

Authors:  W Haefely; J R Martin; P Schoch
Journal:  Trends Pharmacol Sci       Date:  1990-11       Impact factor: 14.819

10.  The effect of benzodiazepines and beta-carbolines on GABA-stimulated chloride influx by membrane vesicles from the rat cerebral cortex.

Authors:  T Obata; H I Yamamura
Journal:  Biochem Biophys Res Commun       Date:  1986-11-26       Impact factor: 3.575

View more
  6 in total

Review 1.  Zopiclone. An update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia.

Authors:  S Noble; H D Langtry; H M Lamb
Journal:  Drugs       Date:  1998-02       Impact factor: 9.546

Review 2.  The diversity of GABAA receptors. Pharmacological and electrophysiological properties of GABAA channel subtypes.

Authors:  W Hevers; H Lüddens
Journal:  Mol Neurobiol       Date:  1998-08       Impact factor: 5.590

Review 3.  Abuse and dependence liability of benzodiazepine-type drugs: GABA(A) receptor modulation and beyond.

Authors:  Stephanie C Licata; James K Rowlett
Journal:  Pharmacol Biochem Behav       Date:  2008-01-12       Impact factor: 3.533

Review 4.  Clinically important drug interactions with zopiclone, zolpidem and zaleplon.

Authors:  Leah M Hesse; Lisa L von Moltke; David J Greenblatt
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

5.  Agitation in the ICU: part one Anatomical and physiologic basis for the agitated state.

Authors: 
Journal:  Crit Care       Date:  1999       Impact factor: 9.097

Review 6.  Pharmacotherapeutic management of insomnia and effects on sleep processes, neural plasticity, and brain systems modulating stress: A narrative review.

Authors:  Laura Palagini; Carlotta Bianchini
Journal:  Front Neurosci       Date:  2022-07-29       Impact factor: 5.152

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.